Abstract:The non-specific biodistribution of traditional chemotherapeutic drugs against tumors is the key factor that causes systemic toxicity and hinders their clinical application. In this study, a reduction-sensitive polymer conjugate micelle was manufactured to achieve tumor-specific targeting, reduce toxic side-effects and improve anti-tumor activity of a natural anti-cancer drug, hydroxycamptothecin (HCPT). Therefore, HCPT was conjugated with methoxy-poly(ethylene glycol)-poly(β-benzyl-L-aspartate) (mPEG-PBLA) by a disulfide bond or succinate bond for the first time to obtain the mPEG-PBLA-SS-HCPT (PPSH) and mPEG-PBLA-CC-HCPT (PPCH) that would form micelles after high-speed agitation and dialysis. The PPSH micelles showed an average particle size of 126.3 nm, a low polydispersity index of 0.209, and a negative surface charge of -21.1 mV zeta potential. Transmission electron microscopy showed the PPSH micelles to have spherical morphology. PPSH had a low critical micelle concentration of 1.29 μg ml-1 with high dilution stability, storage stability and reproducibility. Moreover, the particle size of the PPSH micelles had no significant change after incubation with rat plasma for 72 h, probably resulting in high long circulation in the blood. The PPSH micelles showed significant reduction sensitivity to glutathione. Their sizes increased by 403.2 nm after 24 h post-incubation, and 87.6% drug release was achieved 48 h post-incubation with 40 mM glutathione solutions. The PPSH micelles showed stronger inhibition of HepG2 cells in vitro and growth of H-22 tumor in vivo than the PPCH and HCPT solutions after intravenous injection. The accumulation of PPSH micelles in the tumor tissue contributed to the high anti-tumor effect with little side-effect on the normal tissues. The reduction-sensitive PPSH micelles were a promising carrier of HCPT and other poorly soluble anti-cancer drugs.

Hydroxycamptothecin (HCPT)-loaded PEGlated lipid–polymer hybrid nanoparticles for effective delivery of HCPT: QbD-based development and evaluation

Hydroxycamptothecin-loaded Nanoparticles Enhance Target Drug Delivery and Anticancer Effect.

Preparation and Characterization of Long-Circulating PELMD/mPEG–PLGA-mixed Micelles for 10-Hydroxycamptothecin

Targeted Delivery of 10-Hydroxycamptothecin to Human Breast Cancers by Cyclic RGD-modified Lipid–polymer Hybrid Nanoparticles

Lipid nanoparticles loaded with 10-hydroxycamptothecinphospholipid complex developed for the treatment of hepatoma in clinical application

Linear-like polypeptide-based micelle with pH-sensitive detachable PEG to deliver dimeric camptothecin for cancer therapy

Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice.

Reduction-sensitive Poly(ethylene Glycol)–polypeptide Conjugate Micelles for Highly Efficient Intracellular Delivery and Enhanced Antitumor Efficacy of Hydroxycamptothecin

10-Hydroxycamptothecin (HCPT) nanosuspensions stabilized by mPEG 1000 -HCPT conjugate: high stabilizing efficiency and improved antitumor efficacy.

10-Hydroxycamptothecin loaded nanoparticles: Preparation and antitumor activity in mice

Intracellular target delivery of 10-hydroxycamptothecin with solid lipid nanoparticles against multidrug resistance

Poly(Omega-Pentadecalactone-Co-Butylene-Co-Succinate) Nanoparticles As Biodegradable Carriers for Camptothecin Delivery

Effect of Octreotide-Polyethylene Glycol(100) Monostearate Modification on the Pharmacokinetics and Cellular Uptake of Nanostructured Lipid Carrier Loaded with Hydroxycamptothecine

A polymeric micelle with an endosomal pH-sensitivity for intracellular delivery and enhanced antitumor efficacy of hydroxycamptothecin.

Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance

Development of a Novel Biocompatible Poly(ethylene Glycol)-Block-poly(γ-cholesterol-l-glutamate) As Hydrophobic Drug Carrier

Quercetin-loaded Poly (Lactic-Co-glycolic Acid)-D-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles for the Targeted Treatment of Liver Cancer

Efficient Tumor Targeting of Hydroxycamptothecin Loaded PEGylated Niosomes Modified with Transferrin

Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles

Biotin-Targeted Multifunctional Nanoparticles Encapsulating 10-Hydroxycamptothecin and Apoptin Plasmid for Synergistic Hepatocellular Carcinoma Treatment

In Vitro and in Vivo Anti-Tumor Efficacy of 10-Hydroxycamptothecin Polymorphic Nanoparticle Dispersions: Shape- and Polymorph-Dependent Cytotoxicity and Delivery of 10-Hydroxycamptothecin to Cancer Cells.